Ibogaine occupies a legal gray area in Spain: it is not explicitly listed on Spain's controlled substances schedules, meaning possession and use are not directly criminalized under current narcotics law, though the substance lacks any approved medical or therapeutic status. Last verified: April 2026.

Not Legal Advice. This page summarizes publicly available information for educational purposes. Laws are subject to change and interpretation. Consult a licensed Spanish attorney before making any decisions related to ibogaine.

Current Legal Status

Spain's drug scheduling framework is administered primarily through the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), the national medicines and health products agency, alongside the Ministry of Health. Spain implements the international drug control conventions — the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances — through domestic legislation. Ibogaine (and its primary alkaloid ibogamine) does not appear on the annexes of either convention, and Spain has not added it to any domestic controlled substances list.

Spain's framework for classifying controlled substances has evolved significantly since early decrees in the 1970s. The current operative legal landscape for drug offenses is shaped by:

  • Ley Orgánica 1/1979 and subsequent Penal Code provisions — Articles 368–378 of the Spanish Penal Code (Código Penal) criminalize trafficking, promotion, and facilitation of substances that cause serious harm to health (sustancias que causan grave daño a la salud). Ibogaine's status under this clause is legally ambiguous given that it is not explicitly scheduled.
  • Ley Orgánica 4/2015 de Seguridad Ciudadana (the so-called Ley Mordaza) — This law, which replaced Ley Orgánica 1/1992, addresses public order and allows for administrative sanctions related to drug consumption in public spaces. It does not create criminal liability for private possession of unscheduled substances.
  • AEMPS scheduling and authorization — AEMPS maintains lists of authorized medicinal products and controlled medicines. Ibogaine holds no marketing authorization in Spain and is not classified as a medicinal product, which means it cannot be legally prescribed, dispensed, or commercially distributed as medicine.

The practical consequence of this framework is that ibogaine sits in a gray zone: private possession for personal use is not a criminal offense under the Penal Code (since Spain decriminalized personal drug use generally), but commercial sale, importation for commercial purposes, or administering the substance in a clinical context without authorization raises significant legal uncertainties. There are no religious exemptions or formal carve-outs analogous to those seen in some other jurisdictions.

Treatment Centers

Despite the regulatory ambiguity, ibogaine retreat centers and therapy providers operate in Spain, particularly in rural areas and in regions with less regulatory scrutiny such as parts of Andalusia, Catalonia, and the Basque Country. These operations typically position themselves as wellness retreats or ceremonial/spiritual contexts rather than medical facilities, partly to avoid triggering AEMPS medical authorization requirements.

Because ibogaine is not a scheduled substance in Spain, operators face less direct legal pressure than they would in countries where the compound is explicitly criminalized. However, they operate without formal medical oversight or legal clarity regarding liability, and their legal exposure can depend heavily on how services are advertised and structured.

For a curated directory of vetted providers operating in Spain and nearby, see our full clinic directory.

How People Access Ibogaine in Spain

The following describes how individuals factually access ibogaine in Spain. This is not a recommendation or endorsement of any particular approach.

  • Retreat centers: The most common route is attending a retreat operated by a private provider. These retreats vary significantly in their medical protocols, screening procedures, and staff qualifications. Some engage independent physicians to conduct pre-screening, while others do not.
  • Underground providers: Some individuals access ibogaine through informal networks without any retreat structure. This carries the highest risk given the absence of medical oversight.
  • Travel from abroad: Spanish residents with substance use disorders sometimes seek treatment at more formally regulated centers in other countries and return to Spain for aftercare.
  • Research and personal importation: Ibogaine hydrochloride and iboga root bark are sometimes imported for personal use or research. Because ibogaine is unscheduled, customs interception is not guaranteed but importation for commercial resale would raise legal concerns under broader pharmaceutical regulations.

Recent Legal Developments

No legislation specifically targeting ibogaine has been enacted in Spain in the past two years. However, several broader developments are relevant:

  • Psychedelic policy debate: Academic and clinical interest in psychedelic-assisted therapy — including psilocybin and MDMA — has grown in Spain, with some researchers at Spanish universities conducting or planning observational studies. This has elevated public and regulatory awareness of the broader category of psychoactive compounds used therapeutically, though ibogaine has not been the direct subject of legislative discussion.
  • AEMPS guidance on novel substances: AEMPS has increased scrutiny of wellness retreats offering unauthorized therapeutic interventions. While this has not resulted in specific ibogaine enforcement actions that have been publicly reported, it signals a tightening regulatory environment for operators who make explicit medical claims.
  • European Medicines Agency (EMA) coordination: At the EU level, there is ongoing interest in regulatory pathways for psychedelic medicines. Spain, as an EU member state, would be expected to align with any future EMA scheduling or authorization decisions regarding ibogaine, though none are imminent as of April 2026.
  • Sociedad Española de Psiquiatría Biológica (SEPB): There has been growing professional discussion about evidence-based psychedelic therapies within Spanish psychiatric associations, which may eventually influence regulatory policy.

Risks of Seeking Treatment in Spain

Spain's gray-area status creates specific risks that prospective patients and providers should understand:

  • No quality control standards: Because ibogaine retreats operate outside any licensed healthcare framework, there is no regulatory body verifying the purity of substances used, the qualifications of facilitators, or the adequacy of medical screening. Ibogaine carries real cardiac risks — QT prolongation and fatal arrhythmias have been documented globally — that require proper pre-screening (ECG, full medical history) and on-site monitoring capability.
  • Variable provider quality: The spectrum of providers in Spain ranges from experienced operators with medically supervised protocols to minimally qualified facilitators. Due diligence by prospective clients is essential.
  • Legal exposure for providers: While possession for personal use is not criminalized, a provider who administers ibogaine in a context that results in serious injury or death could face criminal liability under general provisions of the Penal Code related to reckless endangerment or unlicensed medical practice (intrusismo), regardless of ibogaine's unscheduled status.
  • No consumer recourse: Patients who experience adverse outcomes at unregulated retreats have limited formal recourse, as the services exist outside regulated healthcare frameworks.
  • Drug interaction risks: Ibogaine has dangerous interactions with opioids, SSRIs, and numerous other substances. Without mandatory pre-screening, participants may not disclose relevant medications or conditions.

Frequently Asked Questions

Ibogaine is not explicitly scheduled or listed as a controlled substance under Spain's current narcotics framework administered by AEMPS, making it technically unscheduled. However, it also has no approved medical status. This means personal possession is not directly criminalized, but commercial distribution, importation for sale, or administration in a pseudo-medical context carries legal risks under broader provisions of the Spanish Penal Code and pharmaceutical regulations. The situation is a legal gray area, not a clear legal green light.
Criminal arrest for personal possession of ibogaine in Spain is unlikely given that ibogaine is not scheduled and Spain has broadly decriminalized personal drug possession. However, because the legal gray area involves genuine ambiguity — particularly regarding whether ibogaine could be deemed harmful enough to fall under general Penal Code provisions — you cannot rule out police or prosecutorial attention entirely, especially if possession is associated with apparent distribution. Consult a Spanish criminal defense attorney for advice specific to your situation.
Retreat centers operate in Spain, but they do so without formal legal authorization for ibogaine-assisted therapy. They are not licensed by AEMPS or the Ministry of Health to administer ibogaine as a medical treatment. Many structure their offerings as spiritual or wellness retreats to reduce their legal exposure. Their actual legal status is not definitively established, and operators face potential liability under laws governing unlicensed medical practice and general harm provisions. Prospective attendees should research specific providers carefully.
AEMPS — the Agencia Española de Medicamentos y Productos Sanitarios — is Spain's national regulatory authority for medicines and health products, roughly equivalent to the FDA in the United States or the MHRA in the UK. AEMPS maintains the official lists of authorized medicines and controlled substances in Spain. Ibogaine has no marketing authorization from AEMPS and does not appear on its controlled substances schedules. This means ibogaine cannot be legally prescribed by Spanish doctors or dispensed by Spanish pharmacies, and any clinical or quasi-clinical use occurs outside regulated medical channels.
The Ley Mordaza refers to Ley Orgánica 4/2015 de Seguridad Ciudadana, which replaced the earlier Ley Orgánica 1/1992. It is primarily a public order law that allows for administrative fines — not criminal prosecution — for drug consumption or possession in public spaces. For ibogaine specifically, its practical relevance is limited: since ibogaine is not a scheduled substance, it would not straightforwardly trigger administrative sanctions under this law. The Ley Mordaza is more directly relevant to users of scheduled drugs caught consuming in public.
There is no active Spanish legislative proposal to either explicitly criminalize ibogaine or create a formal legal framework for its therapeutic use as of April 2026. The broader psychedelic therapy conversation is growing in European policy and academic circles, which could eventually influence Spain's approach. Any EU-level EMA authorization or scheduling decision would likely prompt Spain to align its domestic rules. For now, the gray area is expected to persist for the foreseeable future, though this could change with shifts in EU drug policy or high-profile adverse events domestically.
Spain's unscheduled gray-area status is broadly similar to Portugal, which also does not specifically schedule ibogaine (though Portugal has its own distinct decriminalization framework for personal drug use). France and Germany have stricter controlled substances frameworks and treat ibogaine differently. The Netherlands has a more active psychedelic therapy research environment but also stricter ibogaine oversight in some respects. Within the Iberian Peninsula, Spain's approach has made it a destination for ibogaine retreats serving clients from countries with outright prohibition, such as the United Kingdom and France.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.